# CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.

> **NCT03381326** · — · UNKNOWN · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 104 (actual)

## Conditions studied

- Prostate Cancer
- Metastatic Cancer
- Castration-resistant Prostate Cancer
- Circulating Tumor Cells

## Interventions

- **PROCEDURE:** blood and FFPE sample collection

## Key facts

- **NCT ID:** NCT03381326
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-12-15
- **Primary completion:** 2019-10
- **Final completion:** 2023-12
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2023-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03381326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03381326, "CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03381326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*